Welcome to our dedicated page for Casi Pharmaceuticals SEC filings (Ticker: CASI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CASI Pharmaceuticals filings document the regulatory record of a foreign private issuer focused on CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. Recent Form 6-K reports disclose clinical and regulatory matters, including the China Drug Registration Certificate for Thiotepa for Injection, along with material agreements incorporated by reference into Form F-3 registration statements.
The filing record also covers capital-structure events such as convertible-note issuances, governance and management changes, Nasdaq delisting proceedings, and the quotation of the company’s ordinary shares on OTCQB under CASIF. These disclosures address board composition, executive responsibilities, financing terms, listing status, and operating-focus changes for the biopharmaceutical business.
Foresite Capital Fund VI, L.P., together with its general partner Foresite Capital Management VI, LLC and James Tananbaum, report beneficial ownership of 787,121 ordinary shares of CASI Pharmaceuticals, representing 5.1% of the outstanding class based on 15,492,581 shares outstanding. All 787,121 shares are reported as directly owned by Foresite Capital Fund VI, with the reporting persons asserting sole voting and sole dispositive power over those shares and no shared power. The filing includes a certification that the securities were not acquired to change or influence control of the issuer and indicates the holdings are held as passive investments. The filers executed a joint filing agreement.